PALM BEACH, Florida, February 7, 2017 /PRNewswire/ --
With Trump sticking to his campaign promises and point of view, coupled with his latest indications on the direction the
industry is heading with concerns about drug prices, FDA approvals and regulations may be infusing somewhat of positive optimism
in to the biotech/pharma industry. Biotechnology and Pharmaceuticals forging forward with developments of note in the
markets include Organovo Holdings, Inc. (NASDAQ: ONVO), Q BioMed, Inc. (OTC: QBIO), Galena Biopharma, Inc. (NASDAQ: GALE),
Pulmatrix, Inc. (NASDAQ: PULM) and Esperion Therapeutics, Inc. (NASDAQ: ESPR).
Q BioMed, Inc. (OTCQB: QBIO) has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the
Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer. The technology will
utilize "uttroside B" and the compound's derivatives as a chemotherapeutic agent against hepatocellular carcinoma. The
preclinical efficacy of uttroside B, a potent saponin, against liver cancer was recently demonstrated in a November 3, 2016 study published in Scientific Reports, a Nature journal. Read this and more news for
Vinergy Resources at: http://marketnewsupdates.com/news/qbio.html
The compound has been isolated and characterized from the leaves of Solanum nigrum Linn, a plant widely used in traditional
medicine. In the Scientific Reports study, researchers showed that in animal models, uttroside B was ten times more cytotoxic to
the HepG2 liver cancer cell line than the only drug currently approved by the Food and Drug Administration for liver cancer.
Uttroside B drastically shrunk tumors in mice bearing human liver cancer xenografts. In addition, in pre-clinical experiments
uttroside B induced cytotoxicity in all liver cancer cell lines, irrespective of their hepatitis B virus status, while being
non-toxic to normal immortalized hepatocytes.
Chemotherapeutic options for liver cancer are limited, and the prognosis of patients remains challenging. According to the
Centers for Disease Control and Prevention, it is the second most common cause of cancer deaths worldwide, claiming approximately
750,000 lives each year. In the US, the American Cancer Society estimates that 39,000 people will be diagnosed with primary liver
cancer in 2017 and that 27,000 will die from the disease this year.
In other industry related market performances and developments:
Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization
of hematology and oncology therapeutics that address unmet medical needs, on Monday announced the results from a meeting of the
Data Safety Monitoring Board (DSMB) for the two investigator-sponsored (IST) combination clinical trials with NeuVax™
(nelipepimut-S) plus trastuzumab. The trials are being run in breast cancer patients to assess the ability of the
combination of trastuzumab and the HER2 vaccine nelipepimut-S (administered with the immunoadjuvant granulocyte macrophage-colony
stimulating factor) to prevent recurrence in the adjuvant setting.
Organovo Holdings, Inc. (NASDAQ: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering
scientific and medical breakthroughs using its 3D bioprinting technology, in Late January announced a collaboration with
Professor Melissa Little and the Murdoch Childrens Research Institute, The Royal Children's
Hospital, Melbourne, Australia to develop an architecturally correct kidney for potential
therapeutic applications. The collaboration has been made possible by a generous gift from the Methuselah Foundation
("Methuselah") as part of its ongoing University 3D Bioprinter Program.
Pulmatrix, Inc. (NASDAQ: PULM) closed up over 29% at $4.98 on Monday trading over 18.9
Million shares by the market close. Pulmatrix, Inc., announced last week that it has entered into a definitive agreement
with several institutional investors to purchase an aggregate of approximately $3.33 million of
shares of common stock in a registered direct offering.
Esperion Therapeutics, Inc. (NASDAQ: ESPR), the lipid management company focused on developing and commercializing
convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density
lipoprotein cholesterol (LDL-C), announced in late January the completion of patient enrollment in the global pivotal Phase 3
long-term safety and tolerability study of bempedoic acid. Enrollment of this study was completed ahead of schedule in
approximately 2,000 patients treated with bempedoic acid or placebo at high cardiovascular disease (CVD) risk with
hypercholesterolemia whose LDL-C is not adequately controlled with current lipid-modifying therapies. Top-line results from this
study are expected by Q2 2018.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which
disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any
company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any
security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or
hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or
interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and
consult a licensed financial professional before considering any level of investing in stocks. All material included herein
is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is
not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a
portion of their investment when investing in stocks. For current services performed MNU has been compensated three
thousand nine hundred dollars for news coverage of the current press release issued by Q BioMed,
Inc. by the company. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future
expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned",
"will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially
from those projected in the forward-looking statements, including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should
consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such
statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to
update such statements.
Contact Information:
Media Contact email: info@marketnewsupdates.com
+1-(561)-325-8757